ImmunityBio, Inc. IBRX Derivative, Gain (Loss) on Derivative, Net
Derivative, Gain (Loss) on Derivative, Net at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DerivativeGainLossOnDerivativeNet.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s derivative, gain (loss) on derivative, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s derivative, gain (loss) on derivative, net?
- ImmunityBio, Inc. (IBRX) reported derivative, gain (loss) on derivative, net of $1.11M in Q1 2026.
- How has ImmunityBio, Inc.'s derivative, gain (loss) on derivative, net changed year-over-year?
- ImmunityBio, Inc.'s derivative, gain (loss) on derivative, net decreased by 80.1% year-over-year, from $5.58M to $1.11M.
- What does derivative, gain (loss) on derivative, net mean?
- This metric tracks the net gain or loss from derivative financial instruments, such as options, swaps, or forward contracts. These instruments are often used for hedging risks or as part of complex financing arrangements. The net result is reported as a non-operating item and can cause significant fluctuations in reported net income.